MPs Warn UK Deals with President Trump are 'Flimsy'.

Government ministers and leading parliamentarians have issued warnings that the United Kingdom's negotiated accords with Washington are "lacking a solid foundation." This follows revelations that a so-called "milestone" deal on pharmaceutical tariffs, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any formal legal text beyond broad headline terms contained within government press releases.

A Deal Without Detail

The US-UK pharmaceuticals agreement, hailed as a "landmark" achievement, exists as an "agreement in principle" without detailed provisions. It has been highlighted that the official announcements from the UK and US governments frame the deal in divergent terms. The British version emphasizes securing "zero per cent tariffs" as a singular success, while the American announcement concentrates on the agreement for the NHS to pay significantly more for new medications.

"There is a serious risk that the UK government has promised concessions to raise drug prices in return for only a assurance from President Trump," stated David Henig, a trade policy analyst. "History shows he has form for not keeping promises."

A Pattern of Unreliability

Worries have been heightened by Washington's recent decision to suspend the high-value digital accord, which was previously called "a transformative pact" in the bilateral relationship. The US pointed to a failure to advance from the UK on addressing wider trade issues as the reason for the pause.

Additionally, concessions promised for British farmers as part of an initial accord have not been formally ratified by the US, despite a looming January deadline. "We have been informed that that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Behind the scenes, ministers have admitted unease that the government's agreements with the US are flimsy and unreliable. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another described the situation as the "prevailing condition" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, chair of the health select committee, stated: "Perhaps most shocking than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a trustworthy negotiator. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Government figures have sought to reduce the possibility of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, seeking certainty on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that volatility is a feature of dealing with the current US leadership. However, they contend that the UK has achieved real benefits for businesses, such as preferential tariff rates compared to other nations. "Securing 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

Nevertheless, problems have arisen in carrying out the broader trade deal. Promised reciprocal agricultural allowances have yet to be finalized, and the assurance to "eliminate duties on UK metals" has is still pending, with tariffs fixed at 25%.

Moving forward, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.